{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:32:12Z","timestamp":1792931532392,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HR16C0001"],"award-info":[{"award-number":["HR16C0001"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003635","name":"Health Insurance Review and Assessment Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ajp.2023.103857","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T21:28:36Z","timestamp":1702157316000},"page":"103857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Safety outcomes of antipsychotics classes in drug-na\u00efve patients with first-episode schizophrenia: A nationwide cohort study in South Korea"],"prefix":"10.1016","volume":"91","author":[{"given":"Dong Yun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Han","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-3287","authenticated-orcid":false,"given":"Rae Woong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajp.2023.103857_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/YCO.0b013e328314b74b","article-title":"Addressing cardiometabolic risk during treatment with antipsychotic medications","volume":"21","author":"Amiel","year":"2008","journal-title":"Curr. Opin. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2023.103857_bib2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/acps.13413","article-title":"Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: a real\u2010world observational study","volume":"145","author":"Brodeur","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.ajp.2023.103857_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4088\/JCP.v68n0104","article-title":"Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial","volume":"68","author":"Chan","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2023.103857_bib4","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1161\/HYPERTENSIONAHA.120.16402","article-title":"Comprehensive comparative effectiveness and safety of first-line \u03b2-blocker monotherapy in hypertensive patients: a large-scale multicenter observational study","volume":"77","author":"Chan You","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ajp.2023.103857_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s13311-014-0318-6","article-title":"Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats","volume":"12","author":"Citraro","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ajp.2023.103857_bib6","first-page":"pyad029","article-title":"Weight gain and metabolic changes in patients with first-episode psychosis or early-phase schizophrenia treated with olanzapine: a meta-analysis","author":"Correll","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.ajp.2023.103857_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","article-title":"Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review","volume":"28","author":"Gao","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"37","key":"10.1016\/j.ajp.2023.103857_bib8","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.3748\/wjg.15.4653","article-title":"Spectrum of anemia associated with chronic liver disease","volume":"15","author":"Gonzalez-Casas","year":"2009","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.ajp.2023.103857_bib9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","article-title":"Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies","volume":"40","author":"Hirsch","year":"2017","journal-title":"Drug Saf."},{"issue":"10","key":"10.1016\/j.ajp.2023.103857_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-019-1220-8","article-title":"Association between antipsychotic medication use and diabetes","volume":"19","author":"Holt","year":"2019","journal-title":"Curr. Diabetes Rep."},{"issue":"10202","key":"10.1016\/j.ajp.2023.103857_bib11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajp.2023.103857_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1440-1819.2001.00875.x","article-title":"Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open\u2010label multicenter study in Japan","volume":"55","author":"Ishigooka","year":"2001","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.ajp.2023.103857_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-10-26","article-title":"Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone","volume":"10","author":"Johnsen","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"9618","key":"10.1016\/j.ajp.2023.103857_bib14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajp.2023.103857_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013881","article-title":"Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode","volume":"7","author":"Keating","year":"2017","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.ajp.2023.103857_bib16","first-page":"6422","article-title":"Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study","volume":"71","author":"Lataster","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.ajp.2023.103857_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000289049","article-title":"Serotonin receptors and their function in sleep, anxiety disorders and depression","volume":"65","author":"Leonard","year":"1996","journal-title":"Psychother. Psychosom."},{"issue":"9896","key":"10.1016\/j.ajp.2023.103857_bib18","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajp.2023.103857_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system","volume":"135","author":"Leung","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ajp.2023.103857_bib20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/JCP.0b013e3181bf613e","article-title":"Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics","volume":"29","author":"Lin","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.ajp.2023.103857_bib21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0706743718777392","article-title":"Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis","volume":"63","author":"Martino","year":"2018","journal-title":"Can. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2023.103857_bib22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.ajp.2023.103857_bib23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.euroneuro.2014.06.013","article-title":"A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities","volume":"24","author":"Michl","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.ajp.2023.103857_bib24","article-title":"Antipsychotic pitfalls: idiopathic intracranial hypertension and antipsychotic-induced weight gain","volume":"13","author":"Namiki","year":"2020","journal-title":"BMJ Case Rep. CP"},{"issue":"1","key":"10.1016\/j.ajp.2023.103857_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ajp.2023.103857_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med. Res. Methodol."},{"issue":"5","key":"10.1016\/j.ajp.2023.103857_bib27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3346\/jkms.2014.29.5.719","article-title":"Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample","volume":"29","author":"Park","year":"2014","journal-title":"J. Korean Med. Sci."},{"issue":"12","key":"10.1016\/j.ajp.2023.103857_bib28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4088\/JCP.v63n1206","article-title":"Predictors of noncompliance in patients with schizophrenia","volume":"63","author":"Perkins","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2023.103857_bib29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/schbul\/sbi032","article-title":"Pharmacological treatments for first-episode schizophrenia","volume":"31","author":"Robinson","year":"2005","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.ajp.2023.103857_bib30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/schbul\/sbv125","article-title":"A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes","volume":"41","author":"Robinson","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.ajp.2023.103857_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv. Outcomes Res. Methodol."},{"key":"10.1016\/j.ajp.2023.103857_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ajp.2023.103857_bib33","doi-asserted-by":"crossref","unstructured":"Sethi, K.D., 2001. Movement Disorders Induced by Dopamine Blocking Agents, Seminars in Neurology. Copyright\u00a9 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New, pp. 059\u2013068.","DOI":"10.1055\/s-2001-13120"},{"key":"10.1016\/j.ajp.2023.103857_bib34","first-page":"366","article-title":"Essential tremor: diagnosis and management","author":"Shanker","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ajp.2023.103857_bib35","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40264-016-0436-7","article-title":"Hepatic safety of atypical antipsychotics: current evidence and future directions","volume":"39","author":"Slim","year":"2016","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.ajp.2023.103857_bib36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.2021.2825","article-title":"Interpreting the results of intention-to-treat, per-protocol, and as-treated analyses of clinical trials","volume":"326","author":"Smith","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ajp.2023.103857_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.711940","article-title":"Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone","volume":"12","author":"Soria-Chacartegui","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ajp.2023.103857_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajp.2017.04.005","article-title":"Clozaphobia: is avoidance of clozapine in diabetes warranted?","volume":"28","author":"Sreeraj","year":"2017","journal-title":"Asian J. Psychiatry"},{"key":"10.1016\/j.ajp.2023.103857_bib39","series-title":"Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology","author":"Stahl","year":"2008"},{"key":"10.1016\/j.ajp.2023.103857_bib40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s007020200033","article-title":"Partial dopamine agonists in the treatment of psychosis","volume":"109","author":"Tamminga","year":"2002","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ajp.2023.103857_bib41","first-page":"11","article-title":"A tool for assessing the feasibility of comparative effectiveness research","volume":"3","author":"Walker","year":"2013","journal-title":"Comp. Eff. Res."},{"issue":"7","key":"10.1016\/j.ajp.2023.103857_bib42","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24163","article-title":"Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia","volume":"5","author":"Wei","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.ajp.2023.103857_bib43","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.4088\/JCP.15m09898","article-title":"Comparative risk of seizure with use of first-and second-generation antipsychotics in patients with schizophrenia and mood disorders","volume":"77","author":"Wu","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.ajp.2023.103857_bib44","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40263-021-00859-0","article-title":"Antipsychotic-induced constipation: a review of the pathogenesis, clinical diagnosis, and treatment","volume":"35","author":"Xu","year":"2021","journal-title":"CNS Drugs"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201823004148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201823004148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:54:14Z","timestamp":1761756854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201823004148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":44,"alternative-id":["S1876201823004148"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2023.103857","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety outcomes of antipsychotics classes in drug-na\u00efve patients with first-episode schizophrenia: A nationwide cohort study in South Korea","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2023.103857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103857"}}